Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rivaroxaban, 10 mg Clear all
Terminated Phase 4 Interventional Results available

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

NCT03196349
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948
View directory record Official record
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions
Acetylsalicylic acid, Clopidogrel, Rivaroxaban
Drug
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

NCT02846532
View directory record Official record
Conditions
Thrombosis
Interventions
Rivaroxaban, Acetylsalicylic Acid
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 8 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 4 Interventional

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

NCT02810704
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thrombosis
Interventions
Enteric Coated Aspirin, Warfarin, Rivaroxaban
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
18,883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

NCT02058199
View directory record Official record
Conditions
Gastric Bypass Status
Interventions
rivaroxaban
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

NCT03172910
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Rivaroxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, (BAY59-7939), Enoxaparine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Results available

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

NCT03864406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cobicistat, Darunavir/Cobicistat, Rivaroxaban
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

NCT01145859
View directory record Official record
Conditions
Venous Thrombosis, Pediatrics
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting Phase 1 Interventional

Excretion of Rivaroxaban in Human Breast Milk

NCT06831474
View directory record Official record
Conditions
Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions
Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

NCT04508023
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

NCT04504032
View directory record Official record
Conditions
COVID-19
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00332020
View directory record Official record
Conditions
Prevention, Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 28, 2026, 8:26 PM EDT
Active, not recruiting Not applicable Interventional

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, PEGPH20
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

NCT02561923
View directory record Official record
Conditions
Healthy
Interventions
Rivaroxaban, Tranexamic acid, Kcentra, a 4-factor PCC, Saline
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 8:26 PM EDT